Influenza virus infection, interferon response, viral counter-response and apoptosis

Shim, Jung Min; Kim, Jinhee; Min, Jiyoung; Kainov, Denis E.

doi:10.20944/preprints201705.0209.v1

Cited by 22 publications

(32 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Alternatively, Bcl-2 inhibitors which were developed to treat certain cancers are anti-apoptotic and have been suggested as potential treatment for influenza. In vitro data showed decreased viral replication and spread due to these agents (206,207). Maintenance of the epithelial barrier and induction of antiviral mechanisms involve IFN signaling during influenza.…”

Section: Targeting Iav and S Pneumoniae At The Mucosal Barriermentioning

confidence: 99%

Respiratory Barrier as a Safeguard and Regulator of Defense Against Influenza A Virus and Streptococcus pneumoniae

et al. 2020

View full text Add to dashboard Cite

The primary function of the respiratory system of gas exchange renders it vulnerable to environmental pathogens that circulate in the air. Physical and cellular barriers of the respiratory tract mucosal surface utilize a variety of strategies to obstruct microbe entry. Physical barrier defenses including the surface fluid replete with antimicrobials, neutralizing immunoglobulins, mucus, and the epithelial cell layer with rapidly beating cilia form a near impenetrable wall that separates the external environment from the internal soft tissue of the host. Resident leukocytes, primarily of the innate immune branch, also maintain airway integrity by constant surveillance and the maintenance of homeostasis through the release of cytokines and growth factors. Unfortunately, pathogens such as influenza virus and Streptococcus pneumoniae require hosts for their replication and dissemination, and prey on the respiratory tract as an ideal environment causing severe damage to the host during their invasion. In this review, we outline the host-pathogen interactions during influenza and post-influenza bacterial pneumonia with a focus on interand intra-cellular crosstalk important in pulmonary immune responses.

show abstract

Section: Targeting Iav and S Pneumoniae At The Mucosal Barriermentioning

confidence: 99%

Respiratory Barrier as a Safeguard and Regulator of Defense Against Influenza A Virus and Streptococcus pneumoniae

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Apoptosis is a host cellular defence mechanism against virus infections generally initiated by the pattern recognition receptors (PRRs). These receptors recognise the attacking viruses and signal to Bcl-2 proteins which leads to mitochondria membrane permeabilisation (MoMP), cytochrome c release and ultimately cell death (Shim, et al [97] ). Bulanova et al identified some safer benzothiazole derivatives (57, 58 & 59) as inhibiting cellular antiapoptotic Bcl-2 proteins (Bcl-2i), which induced the premature cell deaths of RNA/DNA virus infected cells.…”

Section: Irf3 Agonistsmentioning

confidence: 99%

Benzothiazoles as potential antiviral agents

Asiri

Alsayari

Muhsinah

et al. 2020

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objectives The recent viral pandemic poses a unique challenge for healthcare providers. Despite the remarkable progress, the number of novel antiviral agents in the pipeline is woefully inadequate against the evolving virulence and drug resistance of current viruses. This highlights the urgent need for new and improved vaccines, diagnostics and therapeutic agents to obviate the viral pandemic. Key findings Benzothiazole plays a pivotal role in the design and development of antiviral drugs. This is evident from the fact that it comprises many clinically useful agents. The current review is aimed to provide an insight into the recent development of benzothiazole-based antiviral agents, with a special focus on their structure-activity relationships and lead optimisation. One hundred and five articles were initially identified, and from these studies, 64 potential novel lead molecules and main findings were highlighted in this review. Summary We hope this review will provide a logical perspective on the importance of improving the future designs of novel broad-spectrum benzothiazolebased antiviral agents to be used against emerging viral diseases. Benzothiazoles as antiviral agents Yahya I. Asiri et al.

show abstract

“…We believe that emetine and gemcitabine could be also pursued as potential BSAA candidates (31,42,90). ABT-263, also known as navitoclax, is another interesting BSAA, which is, by contrast to other compounds, facilitates death of infected cells without affecting non-infected cells (20,91,92). Hundred and nineteen safe-in-man broad-spectrum antiviral agents (BSAAs) and viruses they inhibit.…”

Section: Database Of Safe-in-man Bsaasmentioning

confidence: 99%

Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents

Andersen¹,

Ianevski²,

Lysvand³

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

Viral diseases are one of the leading causes of morbidity and mortality in the world. Broad-spectrum antiviral agents (BSAAs) are key players in control of human viral diseases. Here, we reviewed the discovery and development process of BSAAs, focusing on compounds with available safety profiles in human. In addition, we summarized the information on approved, investigational and experimental safe-in-man BSAAs in freely accessible database at https://drugvirus.info/. The number of approved BSAAs will be increased as well as their spectrum of indications will be expanded pending the results of further pre-clinical and clinical studies. This will ultimately reinforce the arsenal of available antiviral options and provide better protection of general population from emerging and re-emerging viral diseases.

show abstract

Influenza virus infection, interferon response, viral counter-response and apoptosis

Cited by 22 publications

References 50 publications

Respiratory Barrier as a Safeguard and Regulator of Defense Against Influenza A Virus and Streptococcus pneumoniae

Respiratory Barrier as a Safeguard and Regulator of Defense Against Influenza A Virus and Streptococcus pneumoniae

Benzothiazoles as potential antiviral agents

Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents

Contact Info

Product

Resources

About